Study Design. Prospective, randomized, blinded clinical trial. Objective. To evaluate effectiveness of Oxiplex gel for reduction of pain and associated symptoms after lumbar discectomy. Summary of Background Data. Oxiplex gel (carboxymethylcellulose, polyethylene oxide, and calcium) is used during discectomy to coat the surgical site for reduction of pain and symptoms after lumbar discectomy. Methods. Patients undergoing single-level lumbar discectomy performed by laminectomy or laminotomy and randomized to receive either surgery plus Oxiplex gel (treatment group) or surgery alone (control group) were assessed 6 months after surgery using (1) a quality of life questionnaire (Lumbar Spine Outcomes Questionnaire [LSOQ]) and (2) clinical evaluations.
results from a FDA-monitored clinical trial, which evaluated the safety and effi cacy of the gel in patients undergoing a single-level lumbar laminectomy for removal of a herniated disc.
MATERIALS AND METHODS
The study was a randomized, third-party blinded (study subject, postoperative clinical evaluator, postoperative Lumbar Spine Outcomes Questionnaire [LSOQ] interviewer), multicenter, pivotal clinical trial to evaluate the safety and effectiveness of the gel to reduce postoperative leg and back pain as well as related symptoms after surgery for removal of a herniated lumbar disc at L4-L5 or L5-S1. The clinical protocol was approved by the US Food and Drug Administration under an Investigational Device Exemption, and the study was conducted at 31 different clinical trial sites with approval of the institutional review board at each site. All of the clinical investigators (n = 61) were independent of the sponsor. All subjects signed an informed consent approved by the respective institutional review boards. The informed consent was typically presented to the potential study subject by the site's study coordinator and signed by the subject prior to baseline Quality of Life questionnaire evaluation. Subjects were screened for eligibility in 3 stages. Initial preoperative eligibility assessment included a medical evaluation by an orthopedic spine surgeon or neurosurgeon. Assessments of the lower extremity were grouped for analytical purposes as "musculoskeletal exams" (sitting and standing assessments of pain, spasms, range of motion, straight leg refl ex, and gait) and "neurological exams" (L4-S1 sensory examinations, deep tendon refl exes, motor examinations, as well as bladder and sexual function). The second stage was completion of the baseline LSOQ. The LSOQ is a validated, multi-item, selfreport questionnaire designed to assess a number of factors that are considered relevant in evaluating treatment outcomes in lumbar spinal disorders. This quality-of-life measure was used to assess the subjects' overall reduction in leg and back pain after lumbar surgery, satisfaction with the overall therapy, and subsequent disability. 12 Subjects with signifi cant pain and symptoms as measured by the LSOQ, who met all intraoperative screening criteria, were randomized to either surgery plus gel (treatment) or surgery only (control). Randomization occurred after the discectomy procedure was complete to the point that the surgeon was ready to close the operative site. Subjects were randomized (1:1) to treatment or control according to a computer-generated paradigm, with balanced assignment across the study and on a per center basis. Study subjects were not informed as to group assignment until all data were analyzed.
Postoperative LSOQ assessments were completed by study personnel at an independent, contracted vendor ( via telephone or written contact) 6 months after surgery. All subjects received clinical follow-up evaluations at 6-months postoperatively including physical examination, assessment of lower extremity weakness, testing of neurological function, and laboratory tests. A qualifi ed clinical evaluator performed the postoperative examinations. The clinical evaluator was a medically trained professional who was blinded to the subject's treatment assignment.
INCLUSION/EXCLUSION CRITERIA
Subjects eligible for this study were adults (18-70 years of age) who were scheduled to undergo their fi rst surgical intervention to treat unilateral herniation of their lumbar intervertebral disc. All study subjects had sciatic pain on the same side of their body as the disc herniation. Subjects had radiological evidence (magnetic resonance image study or computed tomography/myelogram) of nerve root compression, and/or confi rmed existence of an extruded or sequestered disc fragment compatible with clinical signs and symptoms at the L4-L5 or L5-S1 level. Subjects entering the study underwent at least 2 weeks of nonoperative treatment without resolution of pain, unless the surgeon decided the subject was experiencing intractable pain or there was progressive loss of neurological function. All subjects had measurable pain and symptoms as determined by the LSOQ. Subjects who received steroids within 4 weeks prior to surgery, a lumbar puncture within 24 hours prior to surgery, or were diagnosed with foraminal stenosis were excluded. Subjects of a current or anticipated worker's compensation claim or party to a current or anticipated personal injury litigation were also excluded. Subjects who experienced any of the following intraoperative criteria were excluded from the study during surgery: dural entry; spinal fusion; multilevel herniation or the need to involve more than 1 level; exploration of contralateral side; or epidural fat placement.
RANDOMIZATION/BLINDING
Randomization, provided by an independent statistician, was site-specifi c and computer-generated in blocks of 4 and 2. Randomization assignment of each subject was determined after intraoperative eligibility criteria were satisfi ed. Sequentially numbered sealed boxes (with a subject identifi cation number) contained either gel (treatment) or an empty, nonsterile syringe (control). The boxes used for the control group mimicked the appearance, weight, and feel of the boxes containing the treatment gel.
Subjects were contacted by study personnel via telephone or mail to complete their self-assessment questionnaires. Both the subject and study personnel were blinded to the treatment assignment throughout the study period. All clinical evaluations were performed by a blinded clinical evaluator. At the time of study completion, the subject signed a document (Study Blind Documentation/Subject Declaration worksheet) confi rming maintenance of the subject blind. The surgeons who applied the gel did not participate in collection of LSOQ or clinical outcomes data. surgical site to the ventral surface of the vertebral lamina. The wound was then closed in routine fashion.
EFFICACY AND SAFETY MEASUREMENTS
Effi cacy was determined at 6 months after surgery by quantitating the following LSOQ parameters: leg pain, back pain, patient satisfaction, and disability days. In addition, a clinical evaluation of neurological and motor function was performed 6 months after surgery. Assessments of adverse events and concomitant therapies were conducted at 1 month, 3 months, and 6 months postoperatively.
STATISTICAL ANALYSIS
The fi nal data analysis was performed by an independent contracted statistician. Primary effi cacy outcome was measured as the change in LSOQ score from baseline for leg pain, back pain, number of disability days, as well as overall subject satisfaction determined at study end. LSOQ scores were calculated using the method described by BenDebba et al . 12 Additional measures of effi cacy included clinical outcome based on changes in neurological evaluation and clinical examination. The study was powered at 80% to show a difference in leg pain at the P value 0.05 or more level based on results from a previous feasibility study. 13 , 14 The analysis populations were: (1) intention-to-treat population, defi ned as all randomized subjects and (2) the evaluable population, defi ned as all randomized subjects who completed the 6-month LSOQ. The analysis of safety was conducted on the intention-to-treat population. The effi cacy analyses were conducted on the evaluable population. For safety analyses, Fisher's exact test was used except where otherwise specifi ed to assess statistical significance and a 2-sided P value less than 0.05 was considered to be signifi cant. The posttreatment change from baseline in LSOQ scores was determined by general estimating equations analysis with supportive subgroup analysis performed by t -test.
An interim analysis was performed by an independent data management safety board after approximately 75% of the subjects were treated to determine safety and if any adjustments in sample size were required due to the results of the control population. There were no safety issues noted and no changes in the study were made. The study was continued until full enrollment was completed.
RESULTS
A total of 2967 patients were preliminarily screened for eligibility; 1836 patients did not meet all of the initial baseline criteria. The study was discussed with 1131 patients, 333 patients refused consent and 11 patients were deemed ineligible after signing the informed consent due to lab abnormalities or multilevel involvement on radiological examination. The second stage of eligibility assessment, baseline LSOQ, was completed by 787 patients. Of the 420 patients who met the baseline LSOQ criteria (367 were screen failures), 19 patients withdrew consent or did not have surgery and 49 patients were found to be ineligible during surgery.
Postoperative follow-up, data collection, and analysis were performed on enrolled subjects only. Subjects were enrolled at the end of surgery after all eligibility criteria had been verifi ed. The number of subjects enrolled was 352: 177 subjects treated with gel and 175 subjects in the surgery-only control group. One control subject dropped out due to reasons unrelated to the study. The number of subjects reported here is 351 (intention-to-treat: treatment, n = 177; control, n = 174). The number of subjects who completed the 6-month LSOQ was 339. The evaluable population at 6 months consisted of: treatment, n = 171; control, n = 168. Demographic variables ( Table 1 ) , preoperative neurological examinations ( Table 2 ) , and LSOQ scores ( Table 3 ) were well balanced at baseline.
SAFETY
No subjects were discontinued from the study due to an adverse event. All adverse events were based on completed clinical evaluations of the subjects and were recorded on the case report forms. No signifi cant differences were found in adverse events ( Table 4 ) or concomitant therapies (data not shown) between treatment and control groups. No fi ndings related to clinical chemistries and hematology were found to be clinically significant. None of the serious adverse events were determined by the investigators to be due to the use of the gel ( Figure 1 ).
Leg Pain
The subjects with back pain scores less than the median level of 63 at baseline (gel, n = 67, 43 ± 23; control, n = 63, 48 ± 20) had similar reductions in leg pain at 6 months ( P = 0.14). However, subjects with median or higher baseline LSOQ back pain scores (median = 63) had signifi cantly greater reductions in leg pain in the treatment group (n = 78, 62 ± 20) compared with the control group (n = 78, 52 ± 27) at 6 months (18% relative change, P = 0.01, Figure 1 ).
Back Pain
The subjects were subgrouped on the basis of the severity of back pain at baseline. An LSOQ score of 63 or more (approximately 55% of the subjects) identifi ed their back pain to be "severe" back pain and is consistent with a subject declaration of pain as "distressing" or "incapacitating." Subjects with LSOQ back pain scores lower than 63 at baseline (gel, n = 67, 24 ± 25; control, n = 63, 25 ± 22) had similar reductions in back pain at 6 months ( P = 0.69). However, subjects with median or higher LSOQ back pain scores ( i.e. , ≥ 63) at baseline had signifi cantly greater reductions in back pain in the treatment group (n = 78, 55 ± 21) compared with the control group (n = 78, 46 ± 24) at 6 months (19% relative change, P = 0.01, Figure 1 ).
Satisfaction
Subjects' satisfaction with their surgical treatment was directly assessed by the LSOQ at the end of the study (month 6) using a 5-point scale shown in Figure 2 (ranging from 1: extreme satisfaction to 5: extreme dissatisfaction). Subjects with LSOQ back pain scores of 63 or more at baseline had signifi cantly greater overall satisfaction in the treatment group (n = 89, 2 ± 1.4) compared with the control group (n = 98, 2.5 ± 1.6) at 6 months ( P = 0.04). Subjects with back pain scores less than 63 at baseline (treatment group, n = 82, 2.2 ± 1.3; control group, n = 70, 1.9 ± 1.9) had similar levels of satisfaction (lower the number, the greater the satisfaction) at 6 months ( P = 0.12). More subjects in the control group reported self-care and performance of housework scores that were worse at 6 months compared with subjects in the treatment group ( Figure 3 ).
Disability
The number of disability days during the 6-month study was signifi cantly greater in the control group (n = 141) compared with the treatment group (n = 145) (mean difference of control group: treatment group results = 2.07 days, 95% CI = 0.003-4.14, P = 0.05).
Reoperation
Seven subjects underwent a reoperation within 3 months after surgery (Figure 4) . Of the 7, 1 subject (0.6%) was from the treatment group and 6 subjects (3.4%) were from the control group ( P = 0.07).
Clinical Evaluations
Clinical evaluations performed on the lower extremity at 6 months after surgery were similar between study groups except for the musculoskeletal examination ( Table 5 ) . Subjects in the control group had more abnormalities in musculoskeletal examination (24%) than subjects in the treatment group (16%).
Sensory Abnormalities
Subjects in the treatment group reported fewer abnormalities in lower extremity including pain, hypoaesthesia, and myalgia (n = 53) than subjects in the control group (n = 84). group. In the challenging group with severe back pain at baseline, subjects in the treatment group experienced significantly greater reductions in leg and back pain. Only 1 subject in the treatment group underwent reoperation during the 6-month study. In contrast, 6 subjects in the control group underwent reoperation. Overall, subjects in the treatment group were signifi cantly more satisfi ed with their treatment and experienced signifi cantly less disability than subjects in the control group. The gel-treated group had no cases of cerebrospinal fl uid (CSF) leaks or related abnormalities. Rodgers et al 11 showed in a rabbit model of lumbar laminectomy that application of the gel over the dura and through the laminectomy/laminectomy site prevented dural adherence to adjacent structures. Furthermore, when the dura was surgically entered, there were no differences in dural repair or healing in rabbits treated with gel compared with surgery-only controls. The absence of CSF leaks in the pivotal clinical study is consistent with preclinical studies. In addition, there have been no reports of CSF leaks Subjects in the treatment group (n = 4) reported fewer sensory abnormalities in the lower extremities than those in the control group (n = 10).
DISCUSSION
The effectiveness of the gel for the reduction of leg and back pain as well as associated symptoms after single-level lumbar discectomy was determined using quality-of-life measures and clinical evaluations. As the study collected data through 6 months after surgery, the condition of the subjects could be determined at a time point that is generally considered predictive of long-term outcome. 12 , 15 The safety results showed no difference between groups. For all effectiveness measures, subjects in the treatment group did better than subjects in the surgery-only group. Physical examinations of subjects in the treatment group at 6 months identifi ed fewer sensory abnormalities in the lower extremity than subjects in the control Figure 4 . Reoperations. During the course of the study, 7 subjects underwent reoperations (Oxiplex gel-treated group, n = 1; control group, n = 6). All of these reoperations occurred within 3 months of the initial operation and occurred at the same lumbar level. of covered tissues. The carboxymethylcellulose component allows for gel adherence to tissues, 30 thereby placing both materials adjacent to tissue surfaces. Coverage of sensory nerves with gel after disc surgery would serve as a barrier to reduce their exposure to and contact with biochemical and cellular pain mediators while preventing adjacent structures from adhering to one another. 10 Fibrosis has received considerable attention as a contributor to sciatica and lumbar back pain after decompression surgery. Kuslich et al 31 and Jou et al 32 found that spinal nerve roots encased in perineural fi brosis were sensitive to external stimulation in patients with prior laminectomies undergoing repeat procedures under minimal anesthesia. Other investigators have published data derived from a preclinical laminectomy model that resulted in a heightened sensitivity to pain. 33 , 34 Pain reduction occurred as a result of polysaccharide coverage of sensory nerves in the epidural space after laminectomy and disc injury. Similar fi ndings were reported by Kato et al . 35 Epidural fi brosis and subsequent tethering of the nerve root to the disc or pedicle (and thereby compression), may also contribute to postsurgical sciatica and lumbar back pain. However, results of clinical outcome studies attempting to correlate adhesion formation with pain have not been consistent, as most patients with epidural fi brosis do not develop symptomatic complaints. 36 -38 The pain is thought to result from entrapment of the nerve root by fi brosis resulting in enhanced related to gel use since the product was introduced outside the United States in early 2002.
Mechanism(s) of Action
Patients with sciatica and severe lumbar back pain comprise a clinically challenging subgroup of patients with disc herniation. Decompression surgery typically improves sciatica more than lumbar back pain. 9 , 10 , 17 , 18 The sensory nerve fi bers predominate on the surface of the annulus fi brosis and along annular tears. 19 , 20 Patients with a herniated lumbar disc often have a greater density of sensory nerves in the annulus fi brosus and epidural space than patients with less severe lumbar back pain. 10 , 20 -23 The wide variety of pain mediators that come in contact with these sensory nerves during and after disc surgery can sensitize neural tissue to postoperative pain and neurological symptoms. 23 -25 In addition, exposed nuclear material can irritate the sensory nerves of the epidural space. 10 , 25 Increase in sensory nerve excitability that can occur after decompression surgery often prolongs sensory nerve sensitization resulting in pain and hyperalgesia long after the surgical procedure. 26 -28 The proposed mechanism of action of the gel is coating the sensory nerves of the epidural space, including the annulus fi brosus, dura, and nerve root, thereby providing a barrier to cellular and biochemical pain mediators that would otherwise lead to postsurgical pain. The polyethylene oxide component of the gel reduces protein deposition 29 on the surface 59 performed a large (N = 270 patients), randomized, controlled study of patients undergoing lumbar surgery for radiculopathy. The incidence of postoperative pain was reduced 50% in gel-treated patients compared with controls (16% vs. 8%). The need for postsurgical therapy was reduced to 3% for the gel-treated patients compared with surgery-only controls (8%). Fransen 40 compared the results of gel-treated patients (N = 184) to those who received Adcon-L (N = 62) after spinal surgery. Both were found to signifi cantly reduce pain after surgery. Guizzardi et al 60 and Assietti et al 61 obtained similar results showing additional benefi t from gel compared with surgery alone. In all of these studies, no signifi cant adverse events were reported that were attributed to gel.
In summary, in this large pivotal study, Oxiplex gel was found to be safe when applied to the laminectomy/laminotomy site after discectomy. There were no CSF leaks in the gel-treated group. There was a general improvement in clinical outcomes (abnormal musculoskeletal examinations; neurological abnormalities) and subject satisfaction in the gel-treated subjects compared with surgery-only controls. Subjects in the treatment group had fewer abnormalities of sensory function as determined by physical examination and fewer reoperations. Although subjects in the treatment group had consistently better outcomes than subjects in the control group, the ability of the LSOQ to measure those differences was limited to subjects with leg pain as well as severe back pain at baseline. Taken together, these data demonstrate multiple improvements in clinical outcome compared with that achieved by surgery alone due to the addition of Oxiplex gel to discectomy for treatment of lumbar herniation.
sensitization. Support for this hypothesis was recently provided by Kobayashi et al , 39 who reported a correlation with sciatic pain, perineural fi brosis, and altered nerve root action potential in patients undergoing lumbar discectomy. Fransen 40 evaluated the extent of epidural fi brosis in a group of 396 patients after single-level disc herniation and presenting with sciatica often associated with lumbar back pain. All subjects were operated upon by the same surgeon in the same institution. Upon completion of a conventional microdiscectomy, the decompressed nerve root and epidural space including the annulus fi brosus were systematically covered with gel. Five patients needed reoperations for recurrent herniation, 2 after less than a week, 1 after 1 month, and 2 within the fi rst year after surgery. During the reoperations, there was little or no epidural fi brosis noted that facilitated dissection and separation of the nerve root from surrounding tissues.
Quality of Life Measures
Clinical evaluation of agents to reduce the incidence and severity of pain and related symptoms after lumbar surgery for discectomy is challenged by utilization of a clinically relevant measure with a metric amenable to rigorous review. Although magnetic resonance imaging of postlaminectomy patients readily identifi es fi brosis at the surgical site, consistent correlation between fi brosis and postsurgical pain is largely unproven. 31 , 37 , 38 , 41 -49 Pain scales are a common method for assessing patient outcome after back surgery; at least 22 scales have been previously developed. 50 Quantifying clinical results with these instruments is confounded by background "noise" inherent in pain analysis. The most widely used statistics are based on simple pre-and posttreatment score comparisons. 50 -56 However, use of a single global statistic does not guarantee that the instrument performs well in all subsets of subjects. 50 -55 The presence of pain alone is a narrow defi nition of outcome that correlates poorly with physical function. 50 , 52 -54 The LSOQ is a multi-item, self-report questionnaire designed to assess a number of factors that are relevant in evaluating treatment outcomes for patients with lumbar spinal disorders. The LSOQ was used in this pivotal study, with the approval of the Food and Drug Administration, as a valid measure of clinical outcomes after lumbar discectomy for herniated discs. LSOQ measures in this study from subjects at 6 months with relatively low back pain at baseline did not show a signifi cant difference between study groups. In contrast, in subjects with severe back pain at baseline, there was a clear difference in measurable leg and back pain at 6 months between study groups, with gel subjects showing statistically signifi cant improvements compared with controls. Sensitivity to detect changes toward the lower end of quality-of-life scales is typically less. The changes in scores and the minimal clinically important change for patients with low initial scores are smaller than for the average patient with these types of outcome measures. 51 , 55 , 57 
Summary of European Publications on Oxiplex Gel
Multiple clinical studies from European investigators have been presented that confi rm and extend the results reported
➢ Key Points
In a subgroup of patients with substantial back pain at baseline, Oxiplex reduced the severity of leg and back pain at 6 months after single-level lumbar discectomy compared with surgery alone. Oxiplex-treated subjects had fewer reoperations and neurological abnormalities at 6 months after removal of herniated discs compared with surgery-only patients. There were no safety issues or spinal fl uid leaks in the 177 patients who received Oxiplex. Oxiplex was easy to apply to the surgical site.
